TB Vaccine Development: COVID-19 Pathways, mRNA Tech Hold Hope

Eyes On BioNTech-Gates Foundation Effort

With fast-tracked development and deployment of COVID-19 vaccines yielding results, experts call for similar urgency and funding impetus to progress new vaccines for TB, which still claims 4,000 lives daily. Over 15 candidates have been in development for years, with hope now abounding around the potential of new platforms like mRNA to accelerate efforts.

TB vaccine
TB Vaccine Development Needs Same Urgency As COVID-19 • Source: Stop TB Partnership

The initial development of COVID-19 vaccines took less than 100 days. In contrast, another killer airborne infectious disease - tuberculosis - hasn’t seen a new vaccine in 100 years and research in the area is acutely starved of funds.

TB has long been one of the deadliest infections faced by humanity, claiming over a billion lives in the past...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from Scrip

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Private Equity Targets Bavarian Nordic But Major Investor Balks

 
• By 

After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.